Singapore: Australia-based TGR BioSciences, a developer of advanced cell-based assay technologies, has signed a license agreement with UK-based Abcam, a producer and distributor of high quality protein research tools.

Under the agreement Abcam will develop and manufacture immunoassay products that incorporate TGR's proprietary CaptSure assay technology. Immunoassays incorporating CaptSure are highly sensitive, offer considerable time savings, and are easy to perform when compared with conventional sandwich immunoassays.

Mr James Murray, general manager of Abcam Eugene, commented that, "We are pleased to have signed the license agreement with TGR. This innovative technology will enable Abcam to continue to develop its high quality immunoassay range by providing even greater choice to customers."

"We're extremely pleased that Abcam, a company at the forefront of product supply and support, has recognised the significant advantages afforded by our CaptSure immunoassay technology," said Ms Anne Hinton, CEO, TGR BioSciences.

"Abcam is recognized around the world for providing the highest quality products and services to the life science community, and we are very excited to see Abcam incorporating our technology in their immunoassay products."